Scott Kopetz, MD, PhD, FACP: Breakthroughs in Combination Therapy for Colorectal Cancer
Scott Kopetz, MD, PhD, FACP, works to improve outcomes for patients with colorectal cancer at The University of Texas MD Anderson Cancer Center.
The trial: Single drugs aimed at inhibiting the BRAF gene have not been effective against BRAF-mutated colorectal cancers. To explore the effectiveness of combing two or three drugs, more than 600 patients with BRAF V600E–mutant colorectal cancer were randomly assigned to one of three groups, each of which was treated with a different combination of drugs.
The results: Median overall survival was significantly improved for both the two-drug (8.4 months) and three-drug (9.0 months) groups compared with standard therapy (5.4 months).
The impact: Median overall survival was significantly improved in patients who received combination therapy compared to patients who received standard therapy.
© 2020. American Society of Clinical Oncology. All rights reserved.